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Background: Metabolic therapy using ketogenic diets (KD) is emerging as an alternative or complementary approach
to the current standard of care for brain cancer management. This therapeutic strategy targets the aerobic fermentation
of glucose (Warburg effect), which is the common metabolic malady of most cancers including brain tumors. The
KD targets tumor energy metabolism by lowering blood glucose and elevating blood ketones (β-hydroxybutyrate).
Brain tumor cells, unlike normal brain cells, cannot use ketone bodies effectively for energy when glucose becomes
limiting. Although plasma levels of glucose and ketone bodies have been used separately to predict the therapeutic
success of metabolic therapy, daily glucose levels can fluctuate widely in brain cancer patients. This can create difficulty
in linking changes in blood glucose and ketones to efficacy of metabolic therapy.
Methods: A program was developed (Glucose Ketone Index Calculator, GKIC) that tracks the ratio of blood glucose to
ketones as a single value. We have termed this ratio the Glucose Ketone Index (GKI).
Results: The GKIC was used to compute the GKI for data published on blood glucose and ketone levels in humans
and mice with brain tumors. The results showed a clear relationship between the GKI and therapeutic efficacy using
ketogenic diets and calorie restriction.
Conclusions: The GKIC is a simple tool that can help monitor the efficacy of metabolic therapy in preclinical animal
models and in clinical trials for malignant brain cancer and possibly other cancers that express aerobic fermentation.
Keywords: Glucose, Beta-hydroxybutyrate, Calorie restriction, Metabolic therapy, Glioblastoma, Warburg effect,
Ketogenic diet, Ketone bodiesIntroduction
Dietary therapy using ketogenic diets is emerging as an
alternative or complementary approach to the current
standard of care for brain cancer management. Progno-
sis remains poor for malignant gliomas in both children
and adults [1-5]. Although genetic heterogeneity is ex-
tensive in malignant gliomas [6-8], the Warburg effect
(aerobic fermentation of glucose) is a common metabolic
malady expressed in nearly all neoplastic cells of these and
other malignant tumors [9-11]. Aerobic fermentation
(Warburg effect) is necessary to compensate for the insuf-
ficiency of mitochondrial oxidative phosphorylation in the
cells of most tumors [9,12-14]. Mitochondrial structure
and function is abnormal in malignant gliomas from both* Correspondence: thomas.seyfried.1@bc.edu
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unless otherwise stated.mice and humans [15-19]. Normal brain cells gradually
transition from the metabolism of glucose to the metabol-
ism of ketone bodies (primarily β-hydroxybutyrate and
acetoacetate) for energy when circulating glucose levels
become limiting [20,21]. Ketone bodies are derived from
fatty acids in the liver and are produced to compensate for
glucose depletion during periods of food restriction [20].
Ketone bodies bypass the glycolytic pathway in the cyto-
plasm and are metabolized directly to acetyl CoA in the
mitochondria [22]. Tumor cells are less capable than nor-
mal cells in metabolizing ketone bodies for energy due to
their mitochondrial defects [2,12,23].
Therapies that can lower glucose and elevate ketone
bodies will place more energy stress on the tumor cells
than on the normal brain cells [12,24]. This therapeutic
strategy is illustrated conceptually in Figure 1, as weentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Relationship of plasma glucose and ketone body levels to brain cancer management. The glucose and ketone (β-OHB) values
are within normal physiological ranges under fasting conditions in humans. We refer to this state as the zone of metabolic management. As
blood glucose falls and blood ketones rise, an individual is predicted to reach the zone of metabolic management. Tumor progression is predicted to
be slower within the metabolic target zone than outside of the zone. This can be tracked utilizing the Glucose Ketone Index. The dashed lines signify
the variability that could exist among individuals in reaching a GKI associated with therapeutic efficacy.
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emotional stress can cause blood glucose levels to vary
making it difficult for some people to enter the predicted
zone of metabolic management [26]. A more stable meas-
ure of systemic energy metabolism is therefore needed to
predict metabolic management of tumor growth. The ratio
of blood glucose to blood ketone bodies β-hydroxybutyrate
(β-OHB) is a clinical biomarker that could provide a better
indication of metabolic management than could measure-
ment of either blood glucose or ketone body levels alone.Methods
The ‘Glucose Ketone Index’ (GKI) was created to track
the zone of metabolic management for brain tumor
management. The GKI is a biomarker that refers to the
molar ratio of circulating glucose over β-OHB, which is
the major circulating ketone body. A mathematical tool
called the Glucose Ketone Index Calculator (Additional
file 1) was developed that can calculate the GKI and moni-
tor changes in this parameter on a daily basis (Equation 1).
The GKIC generates a single value that can assess the re-
lationship of the major fermentable tumor fuel (glucose)
to the non-fermentable fuel (ketone bodies). Because many
commercial blood glucose monitors give outputs in mg/dL,
rather than millimolar (mM), the GKIC converts the units
to millimolar. Included in the program is a unit converter
for both glucose and ketones (β-OHB), which can convert
glucose and ketone values from mg/dL to mM and from
mM to mg/dL (Equations 2, 3, 4, 5). The molecular
weights used for calculations in the GKIC are 180.16 g/mol
for glucose and 104.1 g/mol for β-OHB, which is the major
circulating ketone body measured in most commercialtesting kits. The unit converter allows for compatibility for
a variety of glucose and ketone testing monitors.
Glucose Ketone Index½  ¼ Glucose mg=dLð Þ½ 18:016 g  dLmol 
Ketone mMð Þ½ 
ð1Þ
Glucose mg=dLð Þ½  ¼ Glucose mMð Þ½ 




Glucose mMð Þ½  ¼ Glucose mg=dLð Þ½ 
18:016 g  dLmol
  ð3Þ
Ketone mg=dLð Þ½  ¼ Ketone mMð Þ½ 




Ketone mMð Þ½  ¼ Ketone mg=dLð Þ½ 
10:41 g  dlmol
  ð5Þ
The GKIC can set a target GKI value to help track
therapeutic status. Daily GKI values can be plotted to
allow visual tracking of progress against an initial index
value over monthly periods. Entrance into the zone of
metabolic management would be seen as the GKI value
falls below the set target value (as illustrated in Figure 2).
Additionally, the GKIC can track the number of days
that an individual falls within the predicted target zone.
Results
The GKIC was used to estimate the GKI for humans
and mice with brain tumors that were treated with either
calorie restriction or ketogenic diets from five previously
Figure 2 The Glucose Ketone Index Calculator tracking an individual’s GKI. The individual glucose and ketone values are displayed, along
with the corresponding GKI values. The GKI values are plotted over the course of a month (black line), whereas the GKI target value (1.0) is
plotted as a red line. We consider GKI values approaching 1.0 as potentially most therapeutic.
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uated two pediatric patients; one with an anaplastic as-
trocytoma, and another with a cerebellar astrocytoma
[27]. Both individuals were placed on a ketogenic diet
for eight weeks. During the 8-week treatment period,
GKI dropped from about 27.5 to about 0.7 – 1.1 in the
patients. The patient with the anaplastic astrocytoma,
who did not have a response to prior chemotherapy, had
a 21.7% reduction in fluorodeoxyglucose uptake at the
tumor site (no chemotherapy during diet). The patient
with the cerebellar astrocytoma received standard chemo-
therapy concomitant with the ketogenic diet. Fluorodeox-
yglucose uptake at the tumor site in this patient was
reduced by 21.8%. Quality of life was markedly improved
in both children after initiation of the KD [27].
The second clinical study evaluated a 65-yr-old woman
with glioblastoma multiforme [28]. The patient was
placed on a calorie-restricted ketogenic diet (600 kcal/
day) concomitant with standard chemotherapy and radi-
ation, without dexamethasone, for eight weeks. The pa-
tient’s GKI decreased from 37.5 to 1.4 in the first three
weeks of the diet. No discernible brain tumor tissue was
detected with MRI in the patient at the end of eight weeks
of the calorie restricted ketogenic diet. It is also important
to mention that the patient was free of symptoms while
she adhered to the KD. Tumor recurrence occurred
10 weeks after suspension of the ketogenic diet.
The third study, a preclinical mouse study, evaluated
the effects of diets on an orthotopically implanted CT-
2A syngeneic mouse astrocytoma in C57BL/6 J mice
[29]. Mice were implanted with tumors and fed one of
four diets for 13 days: 1) standard diet fed unrestricted,
2) calorie restricted standard diet, 3) ketogenic diet fed
unrestricted, or 4) calorie restricted ketogenic diet. The
mice fed a standard unrestricted diet and a ketogenicdiet had rapid tumor growth after 13 days, and a GKI of
15.2 and 11.4, respectively. The group fed a calorie re-
stricted standard diet had a significant decrease in tumor
volume after 13 days, along with a GKI of 3.7. The group
fed a calorie restricted ketogenic diet also had a signifi-
cant decrease in tumor volume, along with a GKI of 4.4.
The fourth study evaluated the effects of diets on an
orthotopically implanted CT-2A syngeneic mouse astro-
cytoma in C57BL/6 J mice and an orthotopically im-
planted human U87-MG human xenograft glioma in
BALBc/6-severe combined immunodeficiency (SCID)
mice [30]. Tumors were implanted and grown in the mice
for three days prior to diet initiation. After three days,
mice were maintained on one of three diets for 8 days: 1)
standard diet fed unrestricted, 2) ketogenic diet fed unre-
stricted, or 3) calorie restricted ketogenic diet. Tumor
weights at the end of 8 days were reduced only in the mice
that were fed a calorie restricted diet and experienced a
significant decrease in GKI. Groups of mice that did not
have a reduction in tumor weight had GKI’s that ranged
from 9.6 – 70.0. The groups of mice that had a reduction
in tumor weight had GKI’s that ranged from 1.8 – 4.4.
The fifth study evaluated the effects of diet and radi-
ation on mouse GL261 glioma implanted intracranially
in albino C57BL/6 J mice [31]. The mice were implanted
with tumors, and three days later they were placed on ei-
ther a standard diet fed unrestricted or a ketogenic diet
fed unrestricted. Mice were also assigned to groups that
either received or did not receive concomitant radiation
therapy. Without radiation, mice that were fed a keto-
genic diet had a GKI of 6.4 and had a median survival of
28 days, compared to a GKI of 50.0 and median survival
of 23 days for the standard diet group. With radiation,
mice that were fed a ketogenic diet had a GKI of 5.7 and
a median survival of 200+ days, compared to a GKI of
Table 1 Low Glucose Ketone Index values are related to improved prognoses in humans and mice with brain tumors











Human1 Anaplastic Astrocytoma KD-URa 1 0 5.5 0.2 27.5 No response to standard
chemotherapy
56 5.0 4.6 1.1 FDG uptake at tumor site was
decreased by 21.77%; tumor
margins were unchanged
Cerebellar Astrocytoma KD-UR 1 0 5.5 0.2 27.5 Tumor resected and initiated on
KD while under standard
chemotherapy,after tumor was
radiologically stable by CT
56 4.0 5.5 0.7 FDG uptake at tumor site was
decreased by 21.84%
Notes: Both patients remained in
remission after return to standard
diet for 5 years (Subject 1) and
4 years (Subject 2),at time of
publication
Human2 Glioblastoma KD-Rb 1 0 7.5 0.2g 37.5 Incomplete surgical resection of
tumor; received chemotherapy
and radiation therapy concurrent
with diet
21 3.5 2.5g 1.4
No evidence of tumor by MRI
after concurrent therapy
Notes: Patient stayed on low
calorie diet for an additional
5 months; tumor recurrence
3 months after low-calorie diet
suspension
Mouse3 Mouse CT-2A astrocytoma SD-URc 7 13 9.1 0.6 15.2 Tumor dry weight:55 ± 15mgh
Syngenic (C57BL/6 J) SD-Rd 6 13 5.2 1.4 3.7 Tumor dry weight:7 ± 7 mg
KD-UR 14 13 11.4 1.0 11.4 Tumor dry weight:70 ± 15 mg
KD-R 6 13 5.7 1.3 4.4 Tumor dry weight:14 ± 8 mg
Mouse4 Mouse CT-2A astrocytoma SD-UR 12-14 8 14.0 0.2 70.0 Tumor dry weight:95 ± 25mgh
Syngenic (C57BL/6 J) KD-UR 12-14 8 13.5 0.6 22.5 Tumor dry weight:90 ± 15 mg
KD-R 12-14 8 8.0 1.8 4.4 Tumor dry weight:35 ± 5 mg
Human U87-MG glioma SD-UR 12-14 8 11.5 0.5 23.0 Tumor dry weight:60 ± 10mgh
Xenograft (SCID) KD-UR 12-14 8 11.5 1.2 9.6 Tumor dry weight:60 ± 7 mg
KD-R 12-14 8 5.5 3.0 1.8 Tumor dry weight:37 ± 5 mg
Mouse5 Mouse GL261 glioma SD-UR 19 13 10.0 0.2 50.0 Median survival time:23 days
(C57BL/6-cBrd/cBrd/Cr) KD-UR 19 13 8.9 1.4 6.4 Median survival time:28 days
SD-UR + Rade 11 13 9.7 0.3 32.3 Median survival time:41 days
KD-UR + Rad 11 13 9.7 1.7 5.7 Median survival time:200 + days
1Nebeling et al., 1995 [27]
2Zuccoli et al., 2010 [28]
3Seyfried et al., 2003 [29]
4Zhou et al., 2007 [30]
5Abdelwahab et al., 2012 [31]
aKetogenic diet, unrestricted.
bKetogenic diet, restricted.
c Standard diet, unrestricted.
d Standard diet, restricted.
e Diet with radiation therapy.
f Blood/plasma beta-hydroxybutyrate measurement.
g Urinary ketones were measured.
h Mean ± 95% Confidence Interval.
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group.
In addition to these studies, Table 2 shows a clear as-
sociation of the GKI to the therapeutic action of calorie
restriction against distal invasion, proliferation, and
angiogenesis in the VM-M3 model of glioblastoma. The
data for the GKI in Table 2 was computed from those
mice that were measured for both glucose and ketones
in comparison with the other biomarkers as previously
described [32]. When viewed collectively, the results
from the published reports show a clear relationship be-
tween the GKI and efficacy of metabolic therapy using
either the KD or calorie restriction. Therapeutic efficacy
of the KD or calorie restriction is greater with lower
GKI values than with higher values. The results suggest
that GKI levels that approach 1.0 are therapeutic for
managing brain tumor growth. Further studies will be
needed to determine those GKI values that can most ac-
curately predict efficacy during metabolic therapy involv-
ing diet or procedures that lower glucose and elevate
ketone bodies.
Discussion
We present evidence showing that the GKI can predict
success for brain cancer management in humans and
mice using metabolic therapies that lower blood glucose
and elevate blood ketone levels. Besides ketogenic diets,
other dietary therapies, such as calorie restriction, low
carbohydrate diets, and therapeutic fasting, can also
lower blood glucose and elevate β-OHB levels and can
have anti-tumor effects [24,33-38]. The GKIC was devel-
oped to more reliably and simply predict therapeutic
management for brain cancer patients under these diet-
ary states than could measurements of either blood glu-
cose or ketones alone. The data presented in Tables 1
and 2 support this prediction. Although the GKI is sim-
ple in concept, it has not been used previously to gage
success of various metabolic therapies based on inverse
changes in glucose and ketone body metabolism.
As brain tumor cells are dependent on glucose for sur-
vival and cannot effectively use ketone bodies as an al-
ternative fuel, a zone of metabolic management can be
achieved under conditions of low glucose and elevated
ketones. Ketone bodies also prevent neurological symp-
toms associated with hypoglycemia, such as neuroglyco-
penia, which allows blood glucose levels to be lowered
even further [22,39]. Hence, ketone body metabolismTable 2 Linking the Glucose Ketone Index (GKI) to the therap
proliferation, and angiogenesis in the VM-M3 model of gliob
Treatment Glucose (mM) Ketone (mM) GKI Distal invasion
AL 11.2 ± 0.6 0.7 ± 0.09 15.3 ± 0.9 14 ± 1.8
CR 8.3 ± 0.8 1.32 ± 0.1 6.5 ± 0.9 6 ± 0.9
AL, ad libitum feeding and CR is 60% food reduction for 10 days. Values are Mean ±can protect normal brain cells under conditions that tar-
get tumor cells [40]. The zone of metabolic management
is considered the therapeutic state that places maximal
metabolic stress on tumor cells while protecting the
health and vitality of normal cells [41]. We have pre-
sented substantial data showing that the GKI is validated
in several studies in mice. We feel that prospective valid-
ation of the GKIC will be obtained from future studies
using ketogenic diet therapy in humans with brain can-
cer and possibly other cancers that cannot effectively
metabolize β-OHB for energy, and depend upon glucose
for survival.
The GKI can be useful in determining the success of
dietary therapies that shift glucose- and lactate-based
metabolism to ketone-based metabolism. As a shift to-
ward ketone-based metabolism underscores the utility of
many dietary therapies in treating metabolic diseases
[41,42], the GKI can be used in determining the thera-
peutic success of shifting metabolism in individual patients.
The GKI therefore can be used to study the effectiveness
of dietary therapy in clinical trials of patients under a range
of dietary conditions, with a composite primary endpoint
consisting of lowering the subjects’ GKI. This will allow in-
vestigators to parse the effects of successful dietary inter-
vention on disease outcome from unsuccessful dietary
intervention.
Recent clinical studies assessing the effects of dietary
therapy on brain cancer progression have not measured
both blood glucose and ketone bodies throughout the
study periods [43,44]. Future clinical studies that intend
to assess the effect of dietary therapy on brain tumor
progression should measure both blood glucose and ke-
tone, as these markers are necessary to connect dietary
therapy to therapeutic efficacy. Preclinical studies have
demonstrated a clear linkage between GKI and thera-
peutic efficacy. The GKI will be an important biomarker
to measure in future rigorously designed and powered
clinical studies in order to demonstrate if there is a link-
age between GKI and therapeutic efficacy, as the few
case reports in the literature suggest.
The zone of metabolic management is likely entered
with GKI values between 1 and 2 for humans. Optimal
management is predicted for values approaching 1.0,
and blood glucose and ketone values should be mea-
sured 2–3 hours postprandial, twice a day if possible.
This will allow individuals to connect their dietary intake
to changes in their GKI. As an example, Figure 2 useseutic action of calorie restriction against distal invasion,
lastoma
(photons/sec) Proliferation (Ki67 %) Angiogenesis (vessels/hpf)
48 ± 1.2 15 ± 1.1
34 ± 1.5 7 ± 0.72
SEM. 3-7 mice were evaluated in each group; hpf, high power field.
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ketogenic diet, with a target GKI of 1.0. When an indi-
vidual’s GKI falls below the line denoting the target
metabolic state, the zone of metabolic management is
achieved. Further studies will be needed to establish the
validity of the predicted zone of management.
It has not escaped our attention that the GKIC could
have utility not only for managing brain cancer and pos-
sibly other cancers dependent on glucose and aerobic
fermentation for survival, but also for managing other
diseases or conditions where the ratio of glucose to ke-
tone bodies could be therapeutic. Such diseases and con-
ditions include Alzheimer’s disease, Parkinson’s disease,
traumatic brain injury, chronic inflammatory disease,
and epilepsy [41]. For example, the ketogenic diet has
long been recognized as an effective therapeutic strategy
for managing refractory seizures in children [45,46].
Therapeutic success in managing generalized idiopathic
epilepsy in epileptic EL mice can also be seen when ap-
plying the GKI to the data presented on glucose and β-
OHB [47]. Healthy individuals can utilize the GKIC to
prevent diseases and disorder, and manage general well-
ness. Further studies will be needed to determine the
utility of the GKIC for predicting therapeutic success in
the metabolic management of disease.
Additional file
Additional file 1: Instructions for calculating the GKI using a blood
glucose and ketone monitor.
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